NasdaqGS:BIIBBiotechs
Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen (BIIB)
In May 2026, Biogen’s partner UCB reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate-to-severe active systemic lupus erythematosus, while Biogen and Denali ended development of BIIB122 for idiopathic Parkinson’s disease after the Phase 2b LUMA trial failed to show clinical benefit versus placebo.
Together, these updates highlight how Biogen’s pipeline remains a mix of setbacks in broader neurodegeneration and promise in high-need autoimmune indications such as...